Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients (INTERPRET)
Primary Purpose
Colon Disease
Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
NER1006
MoviPrep
Macrogol 400
Sponsored by
About this trial
This is an interventional treatment trial for Colon Disease focused on measuring colonoscopy, hospitalized patients, bowel preparation
Eligibility Criteria
Inclusion Criteria:
- Inpatients scheduled for elective colonoscopy
- bowel preparation performed inside the hospital
- ≥18 years old
Exclusion Criteria:
- known or suspected ileus
- gastrointestinal obstruction
- gastric retention
- bowel perforation
- toxic colitis, or megacolon
- phenylketonuria
- glucose-6-phosphate dehydrogenase deficiency
- active intestinal bleeding
- emergency colonoscopy
- dementia or illness requiring nasogastric tube for bowel prep administration
- refusal to participate or inability to sign the informed consent
Sites / Locations
- Policlinico Sant'Orsola-Malpighi
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
1L PEG
2L PEG
4L PEG
Arm Description
Patients will be prepared with 1L-PEG-based bowel preparation.
Patients will be prepared with 2L-PEG-based bowel preparation.
Patients will be prepared with 4L-PEG-based bowel preparation.
Outcomes
Primary Outcome Measures
Proportion of patients with adequate colon cleansing
Efficacy will be assessed as the percentage of patients with adequate bowel cleansing, as rated according to the Boston Bowel Preparation Scale (BBPS). This scale gives 0-3 points to each of the three colonic segments (i.e. right colon, transverse colon, and left colon); 0 points are assigned for the worst segment cleansing, whereas at least 2 points stand for adequate segment cleansing. Adequate colon cleansing is defined when at least 2 points are reached in each colonic segment.
Secondary Outcome Measures
Full Information
NCT ID
NCT04708366
First Posted
December 29, 2020
Last Updated
January 12, 2021
Sponsor
University of Bologna
1. Study Identification
Unique Protocol Identification Number
NCT04708366
Brief Title
Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients
Acronym
INTERPRET
Official Title
Colon Cleansing Efficacy With 1L PEG Versus 2L PEG and 4L PEG for Colonoscopy Among Inpatients: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 1, 2021 (Anticipated)
Primary Completion Date
March 15, 2022 (Anticipated)
Study Completion Date
May 15, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Bologna
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
An adequate level of bowel preparation before colonoscopy has an extremely relevant impact on lesion detection and procedure success. The inpatient status represents a well-known independent predictor for inadequate colon cleansing. A recent prospective, multicentre, Italian study among inpatients showed that an adequate colon cleansing was achieved in 60-70% of patients, far below the ideal threshold of 90%. Interestingly, a higher rate of adequate colon cleansing was reported for a very low-volume (1L) polyethylene glycol (PEG)-based preparation when compared to 4L and 2L PEG-based solutions. However, this finding has to be confirmed as the study was not controlled and the PEG-1L group was much smaller than the other two.
Aim of the present multicenter randomized controlled study will be to assess and compare the efficacy and safety of a novel very-low volume (1L) PEG-based preparation vs. standard-of-care low-volume (2L) and high-volume (4L) PEG-based purge, among inpatients who undergo colonoscopy.
Detailed Description
An adequate level of bowel preparation before colonoscopy has an extremely relevant impact on lesion detection and procedure success. The inpatient status represents a well-known independent predictor for inadequate colon cleansing. A recent prospective, multicentre, Italian study among inpatients showed that an adequate colon cleansing was achieved in 60-70% of patients, far below the ideal threshold of 90%. Such a low efficacy has several negative consequences: first, it leads to repetition of colonoscopy, therefore prolonging patients' in-hospital stay and increasing the risk of adverse events and costs; second, it augments the risk of missing colorectal lesions, negatively affecting patients' management and increasing costs due to the need for adjunctive diagnostic studies.
Current recommendations on bowel preparation among difficult-to-prepare patients are mostly based on expert opinions, the high-volume 4L polyethylene glycol (PEG)-based prep being considered as the gold standard, possibly with further additional solution. On the other hand, compliance to the bowel preparation has been related to an adequate colon cleansing, and it may be argued that inpatients might find it difficult to take high-volume purge. A recent Italian prospective multicentre study among inpatients showed similar rates of adequate bowel preparation between patients who underwent bowel preparation with and without additional solution. Interestingly, a higher rate of adequate colon cleansing was reported for a very low-volume (1L) polyethylene glycol (PEG)-based preparation when compared to 4L and 2L PEG-based solutions. However, this finding has to be confirmed as the study was not controlled and the PEG-1L group was much smaller than the other two.
Aim of the present randomized multicenter controlled study will be to assess and compare the efficacy and safety of a novel very-low volume (1L) PEG-based preparation vs. standard-of-care low-volume (2L) and high-volume (4L) PEG-based purge, among inpatients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colon Disease
Keywords
colonoscopy, hospitalized patients, bowel preparation
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
846 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1L PEG
Arm Type
Experimental
Arm Description
Patients will be prepared with 1L-PEG-based bowel preparation.
Arm Title
2L PEG
Arm Type
Active Comparator
Arm Description
Patients will be prepared with 2L-PEG-based bowel preparation.
Arm Title
4L PEG
Arm Type
Active Comparator
Arm Description
Patients will be prepared with 4L-PEG-based bowel preparation.
Intervention Type
Drug
Intervention Name(s)
NER1006
Other Intervention Name(s)
IMP-1
Intervention Description
Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Intervention Type
Drug
Intervention Name(s)
MoviPrep
Other Intervention Name(s)
IMP-2
Intervention Description
Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Intervention Type
Drug
Intervention Name(s)
Macrogol 400
Other Intervention Name(s)
IMP-3
Intervention Description
Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Primary Outcome Measure Information:
Title
Proportion of patients with adequate colon cleansing
Description
Efficacy will be assessed as the percentage of patients with adequate bowel cleansing, as rated according to the Boston Bowel Preparation Scale (BBPS). This scale gives 0-3 points to each of the three colonic segments (i.e. right colon, transverse colon, and left colon); 0 points are assigned for the worst segment cleansing, whereas at least 2 points stand for adequate segment cleansing. Adequate colon cleansing is defined when at least 2 points are reached in each colonic segment.
Time Frame
During the procedure.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Inpatients scheduled for elective colonoscopy
bowel preparation performed inside the hospital
≥18 years old
Exclusion Criteria:
known or suspected ileus
gastrointestinal obstruction
gastric retention
bowel perforation
toxic colitis, or megacolon
phenylketonuria
glucose-6-phosphate dehydrogenase deficiency
active intestinal bleeding
emergency colonoscopy
dementia or illness requiring nasogastric tube for bowel prep administration
refusal to participate or inability to sign the informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lorenzo Fuccio
Phone
+39 051 2143338
Email
lorenzofuccio@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lorenzo Fuccio
Organizational Affiliation
University of Bologna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Policlinico Sant'Orsola-Malpighi
City
Bologna
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Colon Cleansing Efficacy With 1L vs. 2L vs. 4L-PEG for Colonoscopy Among Inpatients
We'll reach out to this number within 24 hrs